דוד

Transcripción

1

2 Estimado Dr. El INSTITUTO MEDICAL PHARMA RESEARCH LATAM LLC, ha seleccionado la Ciudad de México, para la realización de eventos académicos de corte internacional, en el área de alta especialidad: Como Best of ASCO, Best of SABCS, SOIMSS, COEI entre otros, donde se presentan los últimos avances en oncología y los más relevantes trabajos expuestos en sus reuniones anuales. El INSTITUTO MEDICAL PHARMA RESEARCH LATAM LLC tiene enfoque en 4 pilares fundamentales: Educación Médica Continua Difusión de lo más novedoso en Oncología Enfoque en Médicos Adscritos y Residentes Puntos de Re Certificación otorgados por el CMO. Estaremos realmente honrados de tener el privilegio de contar con su presencia en nuestros programa académicos en Oncologia, Radioterapia y Hematologia.

3 BEST OF ASCO 2015 Ciudad de México COMITÉ CIENTÍFICO Dra. Aura Argentina Erazo Valle Solis Presidente Dra. Guadalupe Cervantes Sánchez Participante Dr. Miguel Ángel Farías Alarcón Participante Dra. Aurora Orzechowsky Rallo Participante Registrese aquí!!!

4 BEST OF ASCO 2015 Ciudad de México COORDINADORES Dr. Miguel Farías Dra. Guadalupe Cervantes CMN 20 de Nov Dr. Fco. Ochoa Carrillo Presidente del CMO Dr. Samuel Rivera CMN Siglo XXI IMSS Presidente SMeO Dr. José Barrera Franco Director COE I Maestro de Ceremonias Dr. Antonio Maffuz Dr. Jorge Robles Aviña PEMEX Dr. Omar Macedo Dr. Hector Martinez Said Dr. Miguel Quintana Hosp NAVAL

5 BEST OF ASCO 2015 Ciudad de México P"R"O"F"E"S"O"R"E"S" Dr. Flavia Morales Dra. Brenda Carbajal Dr. Abraham Ruiz García C O E, ISSEMyM Dr. Fernando Aldaco Dra. Guadalupe Cervantes Dra. Guadalupe Diaz Dr. Mario Escobar H Gral de Mexico Dr. Juan Antonio Matus Dr. Alejandro Juárez CMN 20 de Noviermbre Dr. Pabel Miranda Dr. Ivan Casanova INCMNSZ Dra. Cynthia Villarreal Dr. Samuel Rivera CMN Siglo XXI Dr. Hector Gurrola Dra. Erika Ruiz Dr. Daniel Motola Kuba Medica Sur Dra. Perla Perez Dra. Adela Poitevin Medica Sur Dra. Karina Murillo HGZ Ignacio Zaragoza Dra. Vanessa Garcia HGM Dr. Noe Flores HRZ 1 de Octubre Dr. Jorge Alatorre INER Presidente de SMeO Dr. Miguel Farias Dr. Carlos Hernández Hospital Regional Benito Juárez OAXACA Dr. Alejandro Mohar

6 08:00 08:55 INAUGURACIÓN REGISTRO Presidium: Dra Aura Erazo Valle, Dr Fco. Ochoa Carrillo, Dra. Gpe. Cervantes Sanchez, Dr José Barrera Franco, Dra Laura Torrecillas, Lic. David Erazo, Lic. Jorge Garcia 09:10 Primary results, NRG Oncology/ NSABP B-35: A clinical trial of anastrozole(a) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy 09:20 Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. 09:30 Phase III, randomized study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2- positive MBC: Primary results from the MARIANNE study 09:40 10:50 11:20 11:40 Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: First overall survival results from STAMPEDE Defining a molecular subclass of treatment resistant prostate cancer 11:50 Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients with metastatic renal cell carcinoma. 12:00 12:10 13:10 A multi-center randomized controlled trial of mfolfox6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC Study): Preliminary results 13:20 Radiofrecuency ablation combined with chemotherapy for unresecable colorectal liver metastases: Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup (CLOCC) 13:30 SIRFLOX: Randomized phase III trial comparing first-line mfolfox6 +/- bevacizumab versus mfolfox6 + selective internal radiation therapy (SIRT) +/- bev in patients with metastatic colorectal cancer 13:40 13:50 CANCER DE MAMA 09:50 Diagnóstico molecular del cáncer de mama y su impacto en la decisión terapéutica 10:40 mesa redonda GENITO URINARIO GASTRO INTESTINAL - COLORECTAL MIELOMA MULTIPLE FIRST study: Updated overall survival in stem cell transplant-ineligible newly diagnosed multiple myeloma patients treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide. 14:10 Reconocimiento: DRA AURA ERAZO VALLE Vino de Honor COFFEE BREAK CANCER COLO RECTAL UN NUEVO ENFOQUE ENTRATAMIENTO PERZONALIZADO. Dr. Miguel Farias; Maestro de Ceremonias Dr. Flavia Morales Dra. Guadalupe Cervantes Dr. Alejandro Juarez CMN 20 de Noviermbre Dra. Guadalupe Cervantes CMN 20 de Nov Dr. Alejandro Mohar Dr. Fco. Ochoa Carrillo PRESIDENTE DE CMO Dr. Samuel Rivera CMN Siglo XXI IMSS Dra. Perla Perez Dr. Noe Flores HRZ 1 de Octubre Dr. Samuel Rivera CMN Siglo XXI IMSS Dr. Carlos Hernández Hospital Regional Benito Juárez OAXACA Dr. Mario Escobar H Gral de Mexico SSA Dr. Ivan Casanova INCMNSZ Dra. Guisela Hernández Dr. José Luis Barrera COE, ISSEMyM Dra. Deborah Martínez INCMNSZ AMGEN

7 Viernes 9 de Octubre 08:30 Phase III trial of etirinotecan pegol versus Treatment of Physician s Choice in patients with advanced breast cancer whose disease has progressed following anthracycline, taxane and capecitabine: The BEACON study 08:40 Results from a phase 2 study of enzalutamide, an androgen receptor inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) 08:50 The survival benefit offered by the surgical management of lowgrade ductal carcinoma in situ of the breast. 09:00 09:15 10:15 Elective versus therapeutic neck dissection in the clinically node negative early oral cancer: A randomised control trial 10:25 Phase III randomized trial of standard fractionation radiotherapy with concurrent cisplatin versus accelerated radiotherapy with panitumumab in patients with locoregional advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC clinical trials Group HN.6 trial 10:35 10:45 COFFEE BREAK 11:15 Phase III, randomized trial (CheckMate 057) of nivolumab versus docetaxel in advanced non- squamous cell non-small cell lung cancer. 11:25 Final overall survival results of the phase III PROCLAIM trial: Pemetrexed, cisplatin (Cis) or etoposide, Cis plus thoracic radiation therapy followed by consolidation cytotoxic chemotherapy in locally advanced nonsquamous non-small cell lung cancer 11:35 11:45 Cáncer de Mama Hormonosensible y el Reto de Cambiar los Paradigmas 12:05 Cáncer de Mama HER2+. La importancia de la experiencia local 12:25 12:35 Update of progression-free survival and correlitive biomarker analysis from cobrim:phase 3 study of Cobimetinib plus Vemurafenib in advanced BRAF-mutated melanoma 12:55 Efficacy and safety results from a phase III trial of nivolumab alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (CheckMate 067) 13:05 Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma 13:10 13:20 Phase III, randomized, double-blind, multicenter, placebocontrolled trial of rilotumumab plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal juntion cancer: RILOMET-1 study 13:30 Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti PD-1 monoclonal antibody pembrolizumab in KEYNOTE :40 RAINBOW 13:50 TERAPIA LOCAL / TRIPLE NEGATIVO HER 2/ER CABEZA Y CUELLO PULMON MELANOMA GASTRO INTESTINAL PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post- menopausal women with hormone receptor- positive, HER2- negative metastatic breast cancer that progressed on prior endocrine therapy Dra. Brenda Carbajal Dra. Guadalupe Diaz Dr. Pabel Miranda Dr. Antonio Maffuz Presidente SMeO Dr. Hector Gurrola Dra. Adela Poitevin Medica Sur Dr. Jorge Robles Aviña PEMEX Dr. Jorge Alatorre INER Dr. Fernando Aldaco Dr. Omar Macedo Dra. Cynthia Villarreal Dr. Juan Antonio Matus Presidente SMeO Dr. Daniel Motola Kuba Medica Sur Dra. Vanesa Garcia HGM SSA Dr. Miguel Farias Dr. Hector Martinez Said Dr. Abraham Ruiz García C O E, ISSEMyM Dra. Karina Murillo HGZ Ignacio Zaragoza Presidente de SMeO Dr. Miguel Quintana Hosp NAVAL

8 Auditorio INMEGEN Como llegar aquí Tome una foto al codigo QR Obtendra la direccion en su telefono AMPLIO ESTACIONAMIENTO 200 AUTOS SEGURIDAD 24 HRS LAS MEJORES INSTALACIONES CON TECNOLOGIA DE PUNTA

9